BioStock: Chordate Medical’s CEO on US marketing plans

Chordate Medical is initiating a pre-study in the US as a first step in obtaining market authorisation from the FDA for its migraine treatment. The pre-study is expected to be completed in Q1 2021 and will provide clarity as to which pathway is appropriate to achieve market approval in the US. BioStock contacted CEO Anders Weilandt to learn more about the process leading up to FDA approval and the possibilities in the US for the company’s migraine treatment.

Read the full interview with CEO Anders Weilandt at biostock.se:

https://www.biostock.se/en/2021/10/chordate-medicals-ceo-on-us-marketing-plans/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se